Genmab A/S (OTCMKTS:GNMSF – Get Free Report) shares saw an uptick in trading volume on Wednesday. 20,786 shares changed hands during trading, an increase of 712% from the average daily volume of 2,559 shares. The stock last traded at $575.00 and had previously closed at $439.05.
Genmab A/S Price Performance
The firm has a market capitalization of $35.77 billion, a P/E ratio of 45.57 and a beta of 0.75. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The business’s 50 day moving average is $355.78 and its 200-day moving average is $301.61.
Genmab A/S Company Profile
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.
Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.
Recommended Stories
- Five stocks we like better than Genmab A/S
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
- Amkor’s Mobile Business Is Slowing, But Its AI Ambitions Aren’t
- Want to Own a Piece of Professional Sports? This ETF Could Be Your Ticket
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
